SARS-CoV-2 vaccination in patients with GI and hepatobiliary carcinoma: a call for booster vaccination
- PMID: 35882561
- DOI: 10.1136/gutjnl-2022-328169
SARS-CoV-2 vaccination in patients with GI and hepatobiliary carcinoma: a call for booster vaccination
Keywords: CHOLANGIOCARCINOMA; COVID-19; HEPATOBILIARY CANCER; HEPATOCELLULAR CARCINOMA; IMMUNE RESPONSE.
Conflict of interest statement
Competing interests: CB received honoraria for lectures and/ or consultancies from AbbVie, Gilead, Janssen, MSD, ViiV and funding from Dt. Leberstiftung, DZIF, Hector Stiftung, NEAT ID. MAG-C has contributed to advisory boards for Roche, Eisai, BMS, MSD and AZ. MBM received travel expenses and honoraria from Gilead and Virology Education. GJR received travel expenses and honoraria from Gilead. JR has received honoraria for lectures and/or consultancies from Abivax, Galapagos, Gilead, Merck, Janssen, Theratechnologies and ViiV. However, these activities have no potential conflicts of interest with the manuscript.
Comment on
-
One world, one pandemic, many guidelines: management of liver diseases during COVID-19.Gut. 2020 Aug;69(8):1369-1372. doi: 10.1136/gutjnl-2020-321553. Epub 2020 Jun 4. Gut. 2020. PMID: 32499304 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous